• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Kytril (granisetron hydrochloride) injection, tablets and oral solution

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- October 2009

 

Summary View

 

PRECAUTIONS

  • An adequate QT assessment has not been conducted, but QT prolongation has been reported with Kytril. Therefore, Kytril should be used with caution in patients with pre-existing arrhythmias or cardiac conduction disorders, as this might lead to clinical consequences. Patients with cardiac disease, on cardio-toxic chemotherapy, with concomitant electrolyte abnormalities and/or on concomitant medications that prolong the QT interval are particularly at risk.
Drug Interactions
  • QT prolongation has been reported with Kytril. Use of Kytril in patients concurrently treated with drugs known to prolong the QT interval and/or are arrhythmogenic, this may result in clinical consequences.

ADVERSE REACTIONS

  • QT prolongation has been reported with Kytril.
Postmarketing Experience
  • QT prolongation has been reported with Kytril.